Loading data for AGMB — first visit, this takes a few seconds.
AgomAb Therapeutics NV (AGMB)
NasdaqGS: AGMB
· Echtzeitkurs · USD
13.75
+0.02 (0.15%)
Zum Schluss: Aug 19, 2026, 8:00 PM
13.75
+0.00%
Nachbörslich: 4:10 PM
AgomAb Therapeutics NV (AGMB) Stock Price, Analysis & Data
0.15% (1D)
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | 677.16 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -81.6 Mio |
| Beta | n/a |
| EPS (ttm) | -1.57 |
| KGV (TTM) | n/a |
| Forward-KGV | -6.99 |
| KBV (TTM) | 5.24 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | 137,274 |
| Ø Vol. (20D) | 98,035 |
| Eröffnung | 13.81 |
| Vortagesschluss | 13.73 |
| Tagesspanne | 13.59 - 14.36 |
| 52-Wk Range | 8.75 - 17.82 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über AGMB
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule i...
Branche Biotechnology
Sektor Healthcare
IPO Datum Feb 6, 2026
Mitarbeiter 62
Börse NasdaqGS
Tickersymbol AGMB
Website https://www.agomab.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von AgomAb Therapeutics NV 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -62.55 Mio, ein Anstieg von 35.19 %.
Finanzberichte
